Advances in Skin Whitening Agents
Mechanisms, Clinical Applications, and Future Perspectives
Chen Y, Wang E, Li Y, Yang Y, Zhang Z, Wang J, Jiang Y, Zhao C
Journal of Cosmetic DermatologyIn the feed 17 Sep 2026, published online 17 Sep 2026, issue 2026 Sep
Topics: Pigmentary disordersCosmetic, lasers, scars & wounds
Abstract
BACKGROUNDSkin hyperpigmentation disorders are common cosmetic and clinical concerns caused by excessive melanin production, abnormal pigment distribution, or persistent pigment after inflammation. Their heterogeneous pathogenesis and tendency to recur complicate treatment, particularly in patients with darker phototypes.
AIMSTo summarize the molecular basis of melanogenesis and critically link these mechanisms to current and emerging strategies for the management of hyperpigmentation, with particular emphasis on melasma and post-inflammatory hyperpigmentation.
METHODSRelevant mechanistic, clinical, and regulatory literature was narratively synthesized, focusing on melanosome biology, human tyrosinase catalysis, MITF-mediated transcriptional control, topical depigmenting agents, procedural interventions, treatment safety, recurrence, and emerging therapeutic technologies.
RESULTSMelanogenesis is regulated across melanosome biogenesis, tyrosinase-dependent melanin synthesis, and MITF-controlled gene expression. Effective management of melasma and post-inflammatory hyperpigmentation requires rigorous photoprotection and control of disease-specific triggers, combined with appropriate topical or procedural therapy. Established agents include hydroquinone, retinoids, azelaic acid, niacinamide, arbutin derivatives, kojic acid, and vitamin C, while thiamidol and tranexamic acid represent increasingly used options. Chemical peels, microneedling, pigment-selective lasers, and combination approaches may improve refractory pigmentation but are limited by recurrence and treatment-induced dyspigmentation, particularly in darker phototypes. Regulatory distinctions surrounding hydroquinone and emerging approaches, including human-tyrosinase-specific screening, targeted or device-assisted delivery, standardized imaging, and phenotype-informed treatment selection, are also considered.
CONCLUSIONSHyperpigmentation is best managed using a mechanism-based, multimodal, and maintenance-oriented strategy rather than isolated suppression of melanin synthesis.
Abstract from Crossref
DOI 10.1111/jocd.71199 · Not in PubMed: details from Crossref